All Cancer Type | Bladder | Breast | Cervix | Colorectal |
Esophagus | Head & Neck | Liver | Lung | Nasopharynx |
Pancreas | Prostate | Sarcoma | Stomach | Others |
Institution | Study Title | |
HKU | High-Grade Glioma (TAC-GReD)Combination Talazoparib - carboplatin for recurrent high-grade glioma with DNA damage repair deficiency (DDRd) “TAC-GReD” trial |
Click for Details |
HKU | Rectal Adenocarcinoma (UW21-577)_A randomized study of neoadjuvant chemoradiotherapy with or without intensification with the FOLFOXIRI chemo-regimen for high-risk locally advanced rectal cancer |
Click for Details |
HKU | Multiple Cancers (NSCLC, Adenocarcinoma, HNSCC, Cholangiocarcinoma, Pancreatic, Adenocarcinoma Solid Tumor (20210023/UW 22-014 / CTC2265) A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors |
Click for Details |
CUHK | Biliary Tract Cancer (BTC007) A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements |
Click for Details |
CUHK | Biliary Tract Cancer (BTC004) A Phase 3, Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine / Cisplatin versus Placebo Plus Gemcitabine / Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma |
Click for Details |
CUHK | Biliary Tract Cancer (BTC005) A Phase III Randomized, Double-Blind, Placebo-Controlled,Multi-Regional, International Study of Durvalumab in Combination withGemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plusCisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1) |
Click for Details |
CUHK | Cancer Pain (SYM012)A pilot randomized open-labeled study comparing a structured titration method of immediate- and sustained-release oxycodone versus titration of investigators’ choice inadvanced cancer patients in Hong Kong |
Click for Details |
CUHK | Tenosynovial Giant Cell Tumor (TGC001) A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION) |
Click for Details |